Innoviva, Inc.

Innoviva, Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies in the United States and globally. Its royalty portfolio includes several key products: RELVAR/BREO ELLIPTA, a once-daily combination of a LABA (vilanterol) and an inhaled corticosteroid (fluticasone furoate) for asthma and COPD; ANORO ELLIPTA, a once-daily combination of a long-acting muscarinic antagonist (umeclidinium bromide) and a LABA (vilanterol); and GIAPREZA, used to increase blood pressure in adults with septic or other distributive shock. The company also markets XACDURO for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter, XERAVA for complicated intra-abdominal infections, ZEVTERA for staphylococcus aureus bacteremia and other infections, and NUZOLVENCE for uncomplicated urogenital gonorrhea. Additionally, Innoviva is developing bacteriophages for infectious diseases.

Innoviva, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol INVA. The company is headquartered in Burlingame, California, United States, and its financial reporting is conducted in US Dollars (USD). As a US-based company traded on a major US exchange, its stock is accessible to investors through standard brokerage accounts, and all financial data, including earnings and dividends, are reported in USD.

Innoviva, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on the research, development, and commercialization of innovative therapies for a range of diseases, including respiratory conditions, infectious diseases, and cardiovascular issues. The company's portfolio includes both marketed products and pipeline candidates, such as bacteriophages for infectious diseases, positioning it within the broader biotechnology landscape that emphasizes novel biological and pharmaceutical approaches to medicine.

Innoviva, Inc. is headquartered in Burlingame, California, United States. The company serves markets both in the United States and globally. Its products are used to treat patients worldwide, with a focus on respiratory diseases like asthma and COPD, as well as serious infections such as hospital-acquired pneumonia, complicated intra-abdominal infections, and gonorrhea. The company's global reach is supported by strategic partnerships, including a collaboration with Glaxo Group Limited for the development and commercialization of once-daily products for COPD and asthma.

Innoviva generates revenue primarily through its royalty portfolio and the commercialization of its marketed products. The company earns royalties from partnerships, such as its collaboration with Glaxo Group Limited on respiratory products like RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which are used for chronic obstructive pulmonary disease and asthma. Additionally, Innoviva directly markets several products, including GIAPREZA for distributive shock, XACDURO for Acinetobacter pneumonia, XERAVA for intra-abdominal infections, ZEVTERA for staphylococcus aureus bacteremia, and NUZOLVENCE for gonorrhea. The company also invests in research and development, including bacteriophage therapies, which may generate future revenue streams. Its strategic partnership with Sarissa Capital Management LP further supports its business operations.